13 results about "Hyperkalemia" patented technology

The invention discloses a treatment guidance system for a hyperkalemia patient, and the system comprises a data detection unit which obtains the medical history, symptom signs and inspection data of the patient through the butt joint of a hospital information system and a laboratory information system, and carries out the data cleaning and structural processing; the decision analysis unit is used for generating a first treatment scheme based on a pre-stored treatment guide rule base and the real-time data; the scheme guidance unit is used for generating a second treatment scheme according to the feedback of the auditing end and pushing the second treatment scheme to the execution end; the dynamic monitoring unit is used for monitoring indexes such as blood potassium, blood gas, electrocardiogram, blood sugar and urine volume of the patient in real time and triggering treatment adjustment and reexamination reminding according to a preset rule; and the long-term management unit is used for generating a personalized long-term management scheme in combination with etiological analysis. According to the invention, through standardized treatment process, intelligent dose correction, dynamic risk early warning and multi-department cooperation, precise, continuous and closed-loop management of hyperkalemia treatment is realized, the short-term death rate is reduced, and the long-term prognosis of a patient is improved.

The invention relates to the technical field, in particular to a dialysate supply system of a hemodialysis machine, which comprises a concentrated solution supply module, a dialysate mixing module, a concentration detection module, a data storage module, an intelligent control module and a centralized control module, the real-time state of a patient is dynamically analyzed through deep learning, components of dialysate are automatically adjusted, the crossing from a fixed formula to individualized dynamic supply is achieved, and the treatment effect is remarkably improved; secondly, the system can predict the risks of hypotension, hyperkalemia and the like prospectively, and actively intervene in advance, so that the incidence rate of dialysis-related acute complications is reduced; and moreover, the workload of medical staff for frequently and manually adjusting parameters is greatly reduced through automatic intelligent control, so that the medical staff can concentrate on clinical decisions, and medical resource allocation is optimized.

Provided are a polymer medicament for treating hyperkalemia, and a preparation method thereof. Specifically, a polymer is provided, and the polymer includes repeating units obtained by polymerizing a monomer and a crosslinking agent. A molar ratio of the monomer to the crosslinking reagent ranges from 1:0.02 to 1:0.20. The monomer includes an acidic group and a pKa-reducing group next to the acidic group. The acidic group is selected from the group consisting of sulfonic acid group (—SO3−), sulfuric acid group (—OSO3−), carboxylic group (—CO2−), phosphonic acid group (—OPO32−), phosphate group (—OPO32−), and sulfamic acid group (—NHSO3−). The pKa-reducing group is selected from the group consisting of nitro, cyano, carbonyl, trifluoromethyl, and halogen atoms. The crosslinking agent has three or four reaction sites. The polymer can be used to treat hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and / or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention provides compounds of Formula (I) or salts thereof: (Formula (I)) wherein X, L, V, R1, R2, R3 and R4 are as defined herein. The claimed compounds inhibit the enzyme type 2 11-hydroxysteroid dehydrogenase (11-HSD2) and thus stimulate potassium excretion by preventing cortisol from being oxidized to corticosterone and thus making it occupy the mineralocorticoid receptor, and are useful in the treatment of hyperkalemia. # imgabs0 #

This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.

The present invention relates to a method for preventing or treating hyperkalemia in a subject. The method comprises a first-stage dosing regimen in which poly(2-fluoroacrylic acid-pentaerythritol triallyl ether) iron calcium sodium salt is orally administered to the subject 3 times a day, 3 g to 48 g each time, for 2 consecutive days. Optionally, the method comprises a second-stage dosing regimen in which 3 g to 48 g of poly(2-fluoroacrylic acid-pentaerythritol triallyl ether) iron calcium sodium salt is orally administered to the subject once a day or once every other day.

Provided herein are potassium-binding polymers prepared by a polymerization reaction of a monomer and a crosslinking agent, wherein the monomer is a compound of Formula (V), the crosslinking agent is a compound of Formula (VI) and / or a compound of Formula (VII), wherein the variables are as defined in the specification; the present application relates to their use in the treatment or prevention of hyperkalemia.

The present invention is directed to cross-linked cation exchange polymers comprising a fluorine group and an acid group, pharmaceutical compositions of these polymers, compositions of a linear polyol and a salt of such a polymer. Cross-linked cation exchange polymers having beneficial physical properties, including combinations of particle size, particle shape, particle size distribution, viscosity, yield strength, compressibility, surface morphology, and / or swelling ratio are also described. These polymers and compositions are useful for binding potassium in the gastrointestinal tract.

This disclosure pertains to the field of medicinal chemistry and relates to pharmaceutical polymers for the treatment of hyperkalemia and methods for their preparation. Specifically, this document provides potassium-binding polymers prepared by polymerization of monomers and crosslinking agents, wherein the monomers are compounds of formula (V), and the crosslinking agents are compounds of formula (VI) and / or formula (VII), wherein the variables are as defined in this specification; this application relates to their use in the treatment or prevention of hyperkalemia.

The present invention relates to a dry suspension comprising poly(2-fluoroacrylic acid-pentaerythritol triallyl ether) iron calcium sodium salt, a suspending agent, and silicon dioxide or a solid powder flavor, and a preparation method therefor; the present invention further relates to the use of the dry suspension in the treatment of hyperkalemia.

The invention discloses a novel application of a traditional Chinese medicine composition and fenerenone in clinically treating diabetic nephropathy. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-60 parts of abelmoschus manihot flowers, 5-30 parts of tripterygium hypoglaucum roots, 20-60 parts of astragalus membranaceus and 5-20 parts of wine-prepared fructus corni. The combined use of the traditional Chinese medicine composition and the fenerenone has the attenuated synergistic effects of relieving proteinuria, protecting the renal function, relieving clinical symptoms, improving the side effect of fenerenone hyperkalemia and the like on patients with clinical proteinuria diabetic nephropathy; clinical application proves that the traditional Chinese medicine composition has a better treatment effect on diabetic nephropathy compared with fenerenone, and is higher in safety.